Investment Rating - The report maintains a "Positive" investment rating for the industry [8]. Core Insights - IL-25 is identified as a novel target in the Type II inflammation pathway, showing upregulation in atopic dermatitis (AD), psoriasis, and contact dermatitis, indicating its involvement in the progression of these skin inflammatory diseases [2][5][27]. - The drug SM17, developed by Chinese Antibody, is a first-in-class (FIC) IL-17RB monoclonal antibody targeting IL-25, demonstrating promising proof-of-concept (PoC) data in Phase Ib trials for atopic dermatitis, with superior itch relief compared to existing therapies [6][35][42]. Summary by Sections IL-25 as a Target - IL-25, a member of the IL-17 cytokine family, plays a crucial role in host defense and inflammatory diseases, inducing the production of IL-4, IL-5, and IL-13, while inhibiting Th17 differentiation [5][17]. - The upregulation of IL-25 in various skin inflammatory diseases suggests its potential for multi-indication exploration [27]. SM17 Clinical Data - In the Phase Ib trial, 75% of patients in the high-dose group achieved at least a 75% improvement in the Eczema Area and Severity Index (EASI-75) by week 12, compared to 0% in the placebo group, indicating a significant difference of 75% [6][35]. - The high-dose group also showed that 91.7% of patients had a significant reduction in the Peak Pruritus Numeric Rating Scale (PP-NRS) score, with no responders in the placebo group [7][38]. - SM17 demonstrated rapid and deep itch relief, outperforming existing AD therapies while maintaining comparable skin lesion improvement [41][43]. Competitive Landscape - Currently, only two IL-25-targeting candidates, SM17 and XKH001, are in clinical development, indicating a relatively early stage of research for this target compared to more established pathways like IL-17 and IL-4 [6][33]. - The competitive landscape for IL-25 and IL-17RB-targeting drugs is evolving, with several candidates in various stages of development [34].

M&A Dynamics - From June 3 to June 8, there were 63 merger and acquisition (M&A) events involving listed companies, with 16 classified as significant M&A events[9] - Out of the total M&A events, 9 were completed, including 1 significant M&A[9] Policy Updates - The People's Bank of China emphasized the need to optimize systems for listings, M&A, and equity incentives based on technological innovation characteristics[7] - The Shanghai Stock Exchange plans to encourage listed companies to increase dividend payouts and enhance market value management tools[7] Major M&A Events - Notable M&A transactions included Baota Industrial acquiring 100% of Electric Power Investment New Energy for CNY 80,927,000[13] - A total of 4 M&A events involved state-owned enterprises as acquirers during the reporting period[13] M&A Failures - There were 3 failed M&A attempts, including a significant transaction by Guangdong Hongyuan due to a lack of consensus on the final transaction plan[15][17] - The failed transactions involved a total value of CNY 19,800,000 for one of the deals[17] Control Changes - Three companies reported changes in actual control, including Jinzi Ham and Diou Home, with the changes occurring between May 30 and June 5, 2025[19] Market Performance - The restructuring index underperformed the Wind All A index by -0.12% during the reporting period[21] - Over a mid-term view, the restructuring index showed fluctuations within a positive range compared to the Wind All A index[21] Risk Factors - Economic recovery in China is slower than expected, which may increase market uncertainty[26] - Geopolitical risks and uncertainties regarding U.S. policies towards China could negatively impact A-share liquidity[26]

Investment Rating - The report maintains an "Outperform" rating for the Hong Kong stock market [4] Core Insights - The Hong Kong stock market has shown a positive trend with the Hang Seng Index and Hang Seng Tech both increasing by 2.2% this week, indicating a strong performance in the innovation drug and internet sectors [1][12] - There has been a significant inflow of funds into Hong Kong stocks, particularly in the media and pharmaceutical sectors, with an average daily fund strength of +7.4 million HKD, a notable increase from the previous week [2] - Earnings per share (EPS) expectations for the Hong Kong stock market have been revised upward by 0.3%, with the electronics sector leading the revisions [3] Summary by Sections Market Performance - The Hang Seng Index closed at 23,793, reflecting a weekly increase of 2.2% and a year-to-date increase of 18.6% [12] - The performance of various sectors shows that the innovation drug sector rose by 6.1%, while the internet sector increased by 3.5% [1] Fund Flow Analysis - A total of 23 sectors experienced fund inflows, with media and pharmaceuticals seeing the highest inflows of +1.9 million HKD and +1.4 million HKD per day, respectively [2] - The sectors that faced outflows included transportation and home appliances, each with a daily outflow of -0.1 million HKD [2] Earnings Forecast - The overall EPS forecast for the Hong Kong stock market has been adjusted upward by 0.3%, with the electronics sector seeing a 1.1% increase in EPS expectations [3] - The steel sector, however, faced a significant downward revision of -7.7% in EPS expectations [3]

Market Overview - The US stock market experienced declines ahead of the Memorial Day holiday, with the Dow Jones falling 256 points or 0.61% to close at 41,603 points, marking four consecutive days of losses[10] - European markets also weakened, with the Stoxx 600 index dropping 0.93% due to renewed trade tensions following Trump's tariff threats against the EU[10] Currency and Commodities - The US dollar index decreased by 0.8%, reflecting an 8.6% decline year-to-date, while gold prices rose by 2.1% to $3,394.50 per ounce amid increased safe-haven demand[27][28] - Oil prices saw a slight increase, with NY crude oil rising 0.5% to $61.53 per barrel, as market confidence in a potential US-Iran nuclear deal weakened[28] Fixed Income - US Treasury yields fell significantly, with the 10-year yield dropping to 4.51%, a decrease of 1.8 basis points, as investors sought safety amid escalating trade tensions[32] - Asian investment-grade bonds remained strong, with Chinese investment-grade bond spreads narrowing by 2-5 basis points, driven by demand from major companies like Alibaba and Tencent[32] Sector Performance - In the Chinese A-share market, the Shanghai Composite Index fell 0.94% to 3,348 points, with over 4,200 stocks declining, while the healthcare sector showed resilience[16] - The Hong Kong market displayed mixed results, with the Hang Seng Index rising 0.24% and healthcare stocks leading gains, while technology stocks faced pressure[12] Key Corporate Developments - Trump's threats of a 50% tariff on EU imports and pressure on Apple to shift production to the US contributed to market volatility, impacting major tech stocks like Apple, which fell 3.02%[10][12] - Xpeng Motors' new MONA series is expected to significantly boost sales, with projections of 600,000 units contributing to a 10% market share in the 100,000-150,000 RMB price range[8]

一方面，科创板公司出口产品具有鲜明的高毛利率特征。据统计，科创板公司境外销售毛利率中位数达 到40.8%，高于板块整体毛利率水平，这有力印证了凭借创新获取 "溢价" 的竞争策略行之有效。例如， 清越科技抓住海外客户追求PMOLED产品新、奇、特的需求加强产品定制，其境外销售毛利率比境内 销售毛利率高出近25个百分点。 面对全球化浪潮中的波折，科创板公司守正创新，坚定不移实施"出海"战略，汇聚全球资源提升核心竞 争力。2024年，科创板公司境外收入突破4300亿元，同比增长6.1%。高附加值产品出口、技术与资本 并驾齐驱的"出海"模式，渐成科创板公司高质量发展新支点。 境外市场增长动能澎湃 从年报披露情况看，2024年，科创板近八成公司实现境外销售，境外收入合计4303.61亿元，占板块整 体营业收入的三成。境外收入同比增速6.1%，超过板块整体营业收入增速。其中，近四成公司2024年 海外收入同比增幅超过其营业收入总体增幅，173家公司境外收入同比增长超过30%，54家公司境外收 入在10亿元以上。 境外收入增长亮眼，既有海外版图的横向拓展，也不乏细分市场的纵向渗透。据统计，63家科创板公司 产品远销逾50个 ...

Summary of Key Points from the Conference Call Industry Overview - The conference call discusses the performance of the Hong Kong stock market (港股) in 2024, highlighting a recovery trend in overall earnings growth with a 1.2% increase in revenue and a 9.8% year-on-year growth in net profit attributable to shareholders [1][3][6]. Core Insights and Arguments - **Earnings Growth**: The second half of 2024 saw a significant acceleration in earnings, with a year-on-year increase of 13.3% [1][6]. - **Key Sectors Driving Growth**: - The information technology sector benefited from breakthroughs in AI technology, with net profit growth of 77.4% in the software and services sub-sector and 76.4% in the technology hardware and equipment sub-sector [1][10]. - The financial sector, particularly the insurance industry, experienced a 70.8% increase in net profit, while diversified financial services saw a 20.5% growth [1][10]. - The healthcare sector, including pharmaceuticals, biotechnology, and life sciences, improved profitability by nearly 20 percentage points [1][10]. - **Struggling Sectors**: The consumer sector showed weak growth, with significant declines in return on equity (ROE) for household and personal products, and food retail. The optional consumer retail sub-sector's profit growth decreased by 36 percentage points, while media and consumer services saw declines of approximately 18% and 19% respectively [1][11]. Financial Metrics - **Return on Equity (ROE)**: The ROE for Hong Kong stocks rose to 7% in 2024, up from 6.7% in the first half of the year, but still below the average of around 10% since 2016. The DuPont analysis indicated that the increase in asset turnover was the primary driver of the ROE improvement [1][7][8]. - **Revenue Trends**: The revenue growth rate for Hong Kong stocks showed signs of bottoming out, with a 1.2% increase for the year, slightly down from 1.9% in the first half of 2024 [1][5]. Comparative Analysis - **Performance vs. A-shares**: The earnings recovery speed of Hong Kong stocks is superior to that of A-shares, which reported negative growth rates of -0.2% for the year and -0.5% for the first half of 2025 in terms of revenue and -2.7% for both periods in net profit [4][6]. Future Outlook - **Support Factors for 2025**: The global technology cycle is expected to rebound, with the AI-driven industrial revolution continuing to support the performance of the information technology sector. Additionally, macroeconomic policies aimed at stabilizing growth are anticipated to benefit mainland companies, which constitute over 60% of the market [4][12].

Report Summary - The report presents the top ten convertible bonds for May 2025 [1][10] Core Viewpoints - The report provides a detailed analysis of the top ten convertible bonds in May 2025, including their ratings, closing prices at the end of April, conversion premium rates, and P/E ratios of the underlying stocks. It also analyzes the business operations, financial performance, and company highlights of the corresponding issuing companies [10][20][30] Analysis of Each Convertible Bond 1. Zhongte Convertible Bond - Rating: AAA; 4 - month - end closing price: 107.723 yuan; Conversion premium rate: 111.03%; Underlying stock PE - TTM: 11.5 [10] - The company is a globally leading specialized special - steel material manufacturer with an annual production capacity of about 20 million tons. In 2024, its revenue was 109.203 billion yuan (-4.22% y/y), and in Q1 2025, revenue was 26.84 billion yuan (-5.59% y/y) [10] - Company highlights: It is one of the world's most comprehensive special - steel enterprises in terms of variety and specification, with over 20 million tons of annual production capacity. It has a complete industrial chain and is seeking external expansion opportunities [11] 2. Shanlu Convertible Bond - Rating: AAA; 4 - month - end closing price: 109.882 yuan; Conversion premium rate: 53.32%; Underlying stock PE - TTM: 3.7 [20] - The company's main business is road and bridge construction and maintenance. In 2024, its revenue was 71.348 billion yuan (-2.3% y/y), and in Q1 2025, revenue was 9.764 billion yuan (+1.95% y/y) [20] - Company highlights: It has the concept of "China - specific valuations" as its actual controller is the Shandong Provincial State - owned Assets Supervision and Administration Commission. It is expected to benefit from the infrastructure construction plan in Shandong during the 14th Five - Year Plan period [21] 3. Heshun Convertible Bond - Rating: AA -; 4 - month - end closing price: 126.801 yuan; Conversion premium rate: 23.13%; Underlying stock PE - TTM: 11.2 [30] - The company is a high - tech enterprise focusing on the R & D, production, and sales of polyamide 6 slices. In 2024, its revenue was 7.168 billion yuan (+19.11% y/y), and in Q1 2025, revenue was 1.563 billion yuan (-4.63% y/y) [30] - Company highlights: In 2024, the downstream market demand was good. It is promoting multiple new projects and actively expanding into the international market [31] 4. Aima Convertible Bond - Rating: AA; 4 - month - end closing price: 128.524 yuan; Conversion premium rate: 15.7%; Underlying stock PE - TTM: 17.6 [41] - The company is a leading enterprise in the electric two - wheeled vehicle industry. In 2024, its revenue was 21.606 billion yuan (+2.71% y/y), and in Q1 2025, revenue was 6.232 billion yuan (+25.82% y/y) [41] - Company highlights: The subsidy for trading in old vehicles may continue, and the implementation of the new national standard is expected to bring policy dividends and improve the gross profit margin [42] 5. Xingye Convertible Bond - Rating: AAA; 4 - month - end closing price: 116.521 yuan; Conversion premium rate: 24.23%; Underlying stock PE - TTM: 5.7 [51] - The company is one of the first joint - stock commercial banks established with the approval of the State Council and the People's Bank of China. In 2024, its revenue was 212.226 billion yuan (+0.66% y/y), and in Q1 2025, revenue was 55.683 billion yuan (-3.58% y/y) [51] - Company highlights: Its net interest income has grown steadily, asset quality is stable, and the scale has maintained stable growth [52] 6. Yonghe Convertible Bond - Rating: AA -; 4 - month - end closing price: 127.310 yuan; Conversion premium rate: 17.03%; Underlying stock PE - TTM: 32.7 [64] - The company's main business is the R & D, production, and sales of fluorochemical products. In 2024, its revenue was 4.606 billion yuan (+5.42% y/y), and in Q1 2025, revenue was 1.138 billion yuan (+12.36% y/y) [64] - Company highlights: In 2024, the prices of refrigerant products recovered, and the fluorochemical production base project of its subsidiary turned profitable [65] 7. Chongyin Convertible Bond - Rating: AAA; 4 - month - end closing price: 121.159 yuan; Conversion premium rate: 12.33%; Underlying stock PE - TTM: 7.2 [73] - The company is an early local joint - stock commercial bank in the upper reaches of the Yangtze River and Southwest China. In 2024, its revenue was 13.679 billion yuan (+3.54% y/y), and in Q1 2025, revenue was 3.581 billion yuan (+5.3% y/y) [73] - Company highlights: It is expected to benefit from the Chengdu - Chongqing Twin - City Economic Circle strategy. Its asset scale has grown steadily, and it actively follows national strategies [74] 8. Beigang Convertible Bond - Rating: AAA; 4 - month - end closing price: 127.2 yuan; Conversion premium rate: 12%; Underlying stock PE - TTM: 19.2 [85] - The company is located at an important transportation hub. In 2024, its revenue was 7.003 billion yuan (+0.77% y/y), and in Q1 2025, revenue was 1.643 billion yuan (+6.73% y/y) [85] - Company highlights: Its cargo and container throughput have increased, and it has a complete transportation network and is actively exploring the market [86] 9. Huayuan Convertible Bond - Rating: AA -; 4 - month - end closing price: 127.228 yuan; Conversion premium rate: 12.95%; Underlying stock PE - TTM: 26.2 [96] - The company focuses on building a complete vitamin D3 industry chain. In 2024, its revenue was 1.243 billion yuan (+13.58% y/y), and in Q1 2025, revenue was 0.326 billion yuan (-1.18% y/y) [96] - Company highlights: It is a leading enterprise in NF - grade cholesterol and 25 - hydroxyvitamin D3 products. It is expanding its product portfolio and has achievements in the pharmaceutical manufacturing field [98] 10. Yushui Convertible Bond - Rating: AAA; 4 - month - end closing price: 122.423 yuan; Conversion premium rate: 26.22%; Underlying stock PE - TTM: 27.7 [106] - The company is the largest integrated water supply and drainage enterprise in Chongqing. In 2024, its revenue was 6.999 billion yuan (-3.52% y/y), and in Q1 2025, revenue was 1.652 billion yuan (+8.66% y/y) [106] - Company highlights: It has a high market share in Chongqing's water supply and drainage market, is expanding externally, and has achieved good results in cost control [108]